BAKER BROS. ADVISORS LP Q1 2019 Filing
Filed May 15, 2019
Portfolio Value
$15.6T
Holdings
96
Report Date
Q1 2019
Filing Type
13F-HR
All Holdings (96 positions)
| # | Stock | Shares | Value | % Portfolio | Type |
|---|---|---|---|---|---|
| 1 | SGENEURSeattle Genetics, Inc. | 51,049,760 | $3.7T | 23.93% | |
| 2 | INCYIncyte Corporation | 34,271,827 | $2.9T | 18.87% | |
| 3 | ONCBeiGene, Ltd. | 11,959,824 | $1.6T | 10.11% | |
| 4 | ALXNAlexion Pharmaceuticals, Inc. | 8,558,068 | $1.2T | 7.41% | |
| 5 | ACADACADIA Pharmaceuticals Inc. | 39,713,842 | $1.1T | 6.83% | |
| 6 | AMRNAmarin Corporation plc | 43,210,459 | $897.0B | 5.74% | |
| 7 | —Genomic Health, Inc. | 10,198,943 | $714.4B | 4.57% | |
| 8 | BMRNBioMarin Pharmaceutical Inc. | 7,589,294 | $674.2B | 4.32% | |
| 9 | ASNDAscendis Pharma A/S | 3,390,270 | $399.0B | 2.55% | |
| 10 | MRTXEURMirati Therapeutics, Inc. | 2,513,462 | $184.2B | 1.18% | |
| 11 | MDGLMadrigal Pharmaceuticals, Inc. | 1,169,278 | $146.5B | 0.94% | |
| 12 | ARGXargenx SE | 1,019,557 | $127.3B | 0.81% | |
| 13 | BCRXBioCryst Pharmaceuticals, Inc. | 15,118,081 | $123.1B | 0.79% | |
| 14 | HRTXHeron Therapeutics, Inc. | 5,018,104 | $122.6B | 0.79% | |
| 15 | —Clementia Pharmaceuticals Inc. | 3,724,445 | $97.2B | 0.62% | |
| 16 | NBIXNeurocrine Biosciences, Inc. | 1,098,670 | $96.8B | 0.62% | |
| 17 | ARRYEURArray BioPharma Inc. | 3,842,289 | $93.7B | 0.60% | |
| 18 | NVTA1EURInvitae Corporation | 3,902,421 | $91.4B | 0.59% | |
| 19 | —Spark Therapeutics, Inc. | 751,927 | $85.6B | 0.55% | |
| 20 | CBAYUSDCymaBay Therapeutics, Inc. | 5,707,411 | $75.8B | 0.49% | |
| 21 | RYTMRhythm Pharmaceuticals, Inc. | 2,708,200 | $74.2B | 0.48% | |
| 22 | —GW Pharmaceuticals plc | 428,345 | $72.2B | 0.46% | |
| 23 | NBIX 2.25 05/15/24Neurocrine Biosciences, Inc. | 53,270,000 | $72.0B | 0.46% | |
| 24 | 1T7Tricida, Inc. | 1,803,238 | $69.6B | 0.45% | |
| 25 | CERSCerus Corporation | 10,749,937 | $67.0B | 0.43% | |
| 26 | —Audentes Therapeutics, Inc. | 1,715,183 | $66.9B | 0.43% | |
| 27 | —Principia Biopharma Inc. | 1,787,807 | $60.8B | 0.39% | |
| 28 | IM8NInsmed Incorporated | 2,077,601 | $60.4B | 0.39% | |
| 29 | KODKodiak Sciences Inc. | 9,145,115 | $59.7B | 0.38% | |
| 30 | KNSAKiniksa Pharmaceuticals, Ltd. | 3,000,000 | $54.2B | 0.35% | |
| 31 | —MyoKardia, Inc. | 1,016,306 | $52.8B | 0.34% | |
| 32 | —DBV Technologies S.A. | 5,509,560 | $42.5B | 0.27% | |
| 33 | QUREuniQure N.V. | 605,000 | $36.1B | 0.23% | |
| 34 | —Aquinox Pharmaceuticals, Inc. | 10,934,154 | $29.5B | 0.19% | |
| 35 | —Zymeworks Inc. | 1,708,472 | $27.6B | 0.18% | |
| 36 | KRYSKrystal Biotech, Inc. | 784,674 | $25.8B | 0.17% | |
| 37 | —Ra Pharmaceuticals, Inc. | 823,113 | $18.4B | 0.12% | |
| 38 | MRUSMerus N.V. | 1,160,014 | $17.1B | 0.11% | |
| 39 | AXSMAxsome Therapeutics, Inc. | 1,200,000 | $17.1B | 0.11% | |
| 40 | BMRN 0.599 08/01/24BioMarin Pharmaceutical Inc. | 15,000,000 | $15.4B | 0.10% | |
| 41 | —Aimmune Therapeutics, Inc. | 673,908 | $15.1B | 0.10% | |
| 42 | CPRXCatalyst Pharmaceuticals, Inc. | 2,900,000 | $14.8B | 0.09% | |
| 43 | AGLEUSDAeglea BioTherapeutics, Inc. | 1,713,604 | $13.8B | 0.09% | |
| 44 | XNCRXencor, Inc. | 428,120 | $13.3B | 0.09% | |
| 45 | —Idera Pharmaceuticals, Inc. | 4,839,895 | $12.3B | 0.08% | |
| 46 | —Dermira, Inc. | 906,943 | $12.3B | 0.08% | |
| 47 | TPIVDEURMarker Therapeutics, Inc. | 1,500,000 | $9.9B | 0.06% | |
| 48 | GBYSangamo Therapeutics, Inc. | 999,823 | $9.5B | 0.06% | |
| 49 | —Abeona Therapeutics Inc. | 1,288,235 | $9.5B | 0.06% | |
| 50 | —Bellicum Pharmaceuticals, Inc. | 2,677,818 | $9.0B | 0.06% | |
| 51 | ANABAnaptysBio, Inc. | 113,086 | $8.3B | 0.05% | |
| 52 | BDQMAlbireo Pharma, Inc. | 250,000 | $8.1B | 0.05% | |
| 53 | IFRXInflaRx N.V. | 178,987 | $6.8B | 0.04% | |
| 54 | —Spring Bank Pharmaceuticals, Inc. | 613,144 | $6.4B | 0.04% | |
| 55 | —bluebird bio, Inc. | 40,000 | $6.3B | 0.04% | |
| 56 | APLSApellis Pharmaceuticals, Inc. | 313,725 | $6.1B | 0.04% | |
| 57 | —Menlo Therapeutics Inc. | 700,000 | $5.5B | 0.04% | |
| 58 | MGNXMacroGenics, Inc. | 302,600 | $5.4B | 0.03% | |
| 59 | —Syros Pharmaceuticals, Inc. | 574,835 | $5.3B | 0.03% | |
| 60 | PTGXProtagonist Therapeutics, Inc. | 403,893 | $5.1B | 0.03% | |
| 61 | AUTLAutolus Therapeutics plc | 156,773 | $4.9B | 0.03% | |
| 62 | HALOHalozyme Therapeutics, Inc. | 299,969 | $4.8B | 0.03% | |
| 63 | VKTXViking Therapeutics, Inc. | 425,000 | $4.2B | 0.03% | |
| 64 | —Forty Seven, Inc. | 250,000 | $4.0B | 0.03% | |
| 65 | XLRNAcceleron Pharma Inc. | 83,900 | $3.9B | 0.03% | |
| 66 | —Acorda Therapeutics, Inc. | 292,134 | $3.9B | 0.02% | |
| 67 | —Sierra Oncology, Inc. | 2,000,000 | $3.4B | 0.02% | |
| 68 | —La Jolla Pharmaceutical Company | 505,240 | $3.2B | 0.02% | |
| 69 | —Achillion Pharmaceuticals, Inc. | 1,095,359 | $3.2B | 0.02% | |
| 70 | VSAREURAravive, Inc. | 430,885 | $3.0B | 0.02% | |
| 71 | CRNXCrinetics Pharmaceuticals, Inc. | 131,250 | $3.0B | 0.02% | |
| 72 | GLPGGalapagos NV | 25,072 | $3.0B | 0.02% | |
| 73 | ASMBAssembly Biosciences, Inc. | 148,587 | $2.9B | 0.02% | |
| 74 | CCXIEURChemoCentryx, Inc. | 207,029 | $2.9B | 0.02% | |
| 75 | YMABUSDY-mAbs Therapeutics, Inc. | 102,800 | $2.7B | 0.02% | |
| 76 | ALKSAlkermes plc | 67,000 | $2.4B | 0.02% | |
| 77 | ORTXUSDOrchard Therapeutics plc | 125,000 | $2.2B | 0.01% | |
| 78 | NTLAIntellia Therapeutics, Inc. | 128,538 | $2.2B | 0.01% | |
| 79 | GTHXEURG1 Therapeutics, Inc. | 127,236 | $2.1B | 0.01% | |
| 80 | CTMXCytomX Therapeutics, Inc. | 194,377 | $2.1B | 0.01% | |
| 81 | —Harpoon Therapeutics, Inc. | 214,285 | $2.0B | 0.01% | |
| 82 | —Foamix Pharmaceuticals Ltd. | 498,189 | $1.9B | 0.01% | |
| 83 | —Constellation Pharmaceuticals, Inc. | 133,333 | $1.8B | 0.01% | |
| 84 | GLMDGalmed Pharmaceuticals Ltd. | 215,594 | $1.8B | 0.01% | |
| 85 | RCUSArcus Biosciences, Inc. | 121,534 | $1.5B | 0.01% | |
| 86 | —Molecular Templates, Inc. | 254,230 | $1.5B | 0.01% | |
| 87 | —Adamas Pharmaceuticals, Inc. | 172,630 | $1.2B | 0.01% | |
| 88 | —ContraFect Corporation | 2,914,536 | $1.2B | 0.01% | |
| 89 | INFIQInfinity Pharmaceuticals, Inc. | 580,400 | $1.1B | 0.01% | |
| 90 | —Affimed N.V. | 200,000 | $840.0M | 0.01% | |
| 91 | FLGTFulgent Genetics, Inc. | 125,000 | $744.0M | 0.00% | |
| 92 | AQSTAquestive Therapeutics, Inc. | 99,600 | $688.0M | 0.00% | |
| 93 | —Sunesis Pharmaceuticals, Inc. | 556,665 | $676.0M | 0.00% | |
| 94 | DVAXDynavax Technologies Corporation | 75,000 | $548.0M | 0.00% | |
| 95 | TREURTrillium Therapeutics Inc. | 505,262 | $333.0M | 0.00% | |
| 96 | —Ritter Pharmaceuticals, Inc. | 279,999 | $244.0M | 0.00% |